Full Version | Search

The Irish Medicines Board - www.imb.ie

IMB Logo

Onglyza (saxagliptin) - Important Safety Information from Bristol-Myers Squibb as approved by the Irish Medicines Board

12 March 2012

Important Safety Information communication from Bristol-Myers Squibb on the association of Onglyza (saxagliptin) with serious hypersensitivity reactions and acute pancreatitis.

Important Safety Information - Onglyza





Date Printed: 23 May 2013

© Irish Medicines Board 2013 | Developed by Engine Solutions www.engine.ie

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971